Search Results
#
Oct 28, 2022, 4:25 PM
Final report of year one.
#
Oct 11, 2022, 4:12 PM
Final update by Dr. Bosnakovski.
#
Aug 23, 2022, 4:51 PM
FSHD Clinical Trial Research Network Quarterly Newsletter - Summer 2022
#
Aug 4, 2022, 12:47 PM
Dr. Ozes provides a brief update on progress in testing quite novel DUX4 inhibitors.
#
May 13, 2022, 11:54 PM
Final report from Dr. Tapscott on his multi-year grant program.
#
Mar 3, 2022, 9:17 AM
Fulcrum Therapeutics, Inc. announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with FSHD, in the second quarter of 2022.
#
Mar 1, 2022, 11:22 AM
Dr. Hiramuki provides a final project update.
#
Feb 7, 2022, 12:46 PM
Dr. Heher provides an update on his innovative mitochondria-targeted antioxidants research.
#
Dec 8, 2021, 3:38 PM
Dr. Bosnakovski provides an initial update on his project.
#
Nov 20, 2021, 10:55 AM
Dr. Harper provides a final update on grant progress.
#
Nov 20, 2021, 10:22 AM
Dr. Marusak provides an interim update on grant progress.
#
Oct 14, 2021, 8:05 PM
Dr. Saad provides a final update on his grant progress.
#
Sep 24, 2021, 4:38 PM
Dr. Ozes provides an update to his successful work in finding a potential small molecule inhibitor for DUX4.
#
Jun 4, 2021, 10:33 AM
Dr. Tapscott provides an update to his multi-year grant.
#
Apr 20, 2021, 1:09 PM
Dr. Rajanikanth Vangipurapu provides an update on the first year of progress.
#
Apr 18, 2021, 10:57 AM
Dr. Harper provides an update on his project.
#
Feb 1, 2021, 7:53 PM
Dr. Saad provides a 6-month update on his work.
#
Dec 1, 2020, 10:36 AM
Dr. Marusak provides a one-year update on their progress.
#
Nov 21, 2020, 9:52 AM
Dr. Tapscott and provides an update on his multi-year grant.
#
Nov 15, 2020, 12:56 PM
In June 2020 Friends of FSH Research partnered with the FSHD Society in an externally led patient-focused drug development meeting. The report is now available.
#
Oct 25, 2020, 5:09 PM
Dr. Rashnonejad provides an update on a potential therapeutic.
#
Jun 19, 2020, 5:16 PM
Dyne has produced a wonderful "Fireside" video for World FSHD Day.
#
Jun 3, 2020, 4:07 PM
In celebration of World FSHD Day and in support of the upcoming Voice of the Patient Forum, Molly White of Dyne Therapeutics invites anyone living with FSHD to describe what would be a meaningful benefit from a successful therapy.
#
May 20, 2020, 3:24 PM
Dr. Tapscott provides an update on his multi-year grant.
#
May 20, 2020, 2:41 PM
Dr. Marusak provides an update on progress so far.
#
May 19, 2020, 2:22 PM
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
May 13, 2020, 1:46 PM
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.
#
Mar 10, 2020, 1:46 PM
Latest progress from Yosuke Hiramuki.
#
Feb 1, 2020, 3:58 PM
Slideshow on aberrant translation which was presented at the Wellstone Research Update 2020 by Sujatha Jagannathan PhD.
#
Jan 31, 2020, 4:05 PM
Slideshow on epigenetics which was presented at the Wellstone Research Update 2020 by Peter Jones PhD.
#
Jan 30, 2020, 8:58 AM
Fulcrum Therapeutics announced that the FDA has granted Orphan Drug Designation to losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.
#
Jan 28, 2020, 1:31 PM
Rashnonajad provides the initial progress update showing efficiently reduced DUX4 mRNA and consequently DUX4 protein in FSHD cells.
#
Jan 9, 2020, 10:37 AM
The Friends of FSH Research is partnering with the FSHD Society on a landmark Voice of the Patient Forum for Drug Development.
#
Nov 24, 2019, 7:35 PM
The funding provided by Friends of FSH Research and the Carrino Foundation has supported Dr. Amy Campbell, a dedicated professional highly skilled in FSHD research who oversees the completion of high-impact studies on FSHD and provides scientific and technical oversight for graduate students, postdoctoral fellows, and collaborators seeking to initiate and/or advance projects in FSHD.
#
Oct 24, 2019, 4:35 PM
Yosuke Hiramuki provides an update on his novel mouse model.
#
Sep 29, 2019, 6:37 PM
Final progress update.
#
Aug 19, 2019, 11:14 AM
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD.
#
Jul 26, 2019, 4:17 PM
Recipient of the FSH Fellowship award.
#
May 29, 2019, 8:16 AM
The funding provided by Friends of FSH Research and the Carrino Foundation has supported Dr. Amy Campbell, a dedicated professional highly skilled in FSHD research who oversees the completion of high-impact studies on FSHD and provides scientific and technical oversight for graduate students, postdoctoral fellows, and collaborators seeking to initiate and/or advance projects in FSHD.
#
Apr 23, 2019, 5:20 PM
Fulcrum Therapeutics today announced an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization of the investigational drug losmapimod.
#
Apr 13, 2019, 3:48 PM
New quarterly publication for the FSHD Clinical Trial Research Network.
#
Apr 1, 2019, 4:12 PM
Video by Dr. Leo Wang about the ReSolve Study - Clinical Trial Preparedness to Solve Barriers to Drug Development in FSHD.
#
Dec 27, 2018, 11:06 AM
Jocelyn Eidahl provides a progress update on the past 6 months of investigating the role of post-translational modification on FSHD protein DUX4.
#
Dec 3, 2018, 10:07 AM
Amy Campbell provides a brief update of her work overseeing lab personnel, publications, etc.
#
Aug 31, 2018, 12:01 PM
Fabiola Bertinotti writes about her week in Vienna as a member of the TREAT-NMD Advisory Committee for Therapeutics (TACT).
#
Aug 1, 2018, 1:00 AM
Dr. Tawil discusses his historical relationship with FSHD and the future of potential therapies.
#
Jul 11, 2018, 9:34 AM
Yi-Wen Chen DMV PhD provides an update on investigating 3rd generation oligonucleotides.
#
Jul 10, 2018, 7:42 PM
Michael Kyba's lab shows that functional skeletal muscle stem cells can be produced from mouse pluripotent stem cells without genetic modification through teratoma formation. As few as 40,000 teratoma-derived cells can regenerate 80% of total muscle volume, improve force generation, and mature into functional muscle stem cells in vivo.
#
Jun 15, 2018, 1:44 AM
Grant recipient Premi Haynes discusses her work and interest in FSHD.
#
Jun 1, 2018, 7:48 AM
Genea Biocells announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its therapeutic candidate, GBC0905,
#
May 25, 2018, 11:43 AM
As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures and optimize eligibility criteria by testing 160 patients in 7 sites over a period of 18 months.
#
Feb 1, 2018, 9:51 PM
Slide decks for Dr. Tapscott & Dr. Wang from the 27-Jan presentations.
#
Jan 1, 2018, 9:01 PM
Yi-Wen Chen DMV PhD provides an update on investigating 3rd generation oligonucleotides.
#
Nov 8, 2017, 7:58 PM
Scott Q. Harper, PhD presents emerging molecular therapies for FSHD at FSHD Global event.
#
Oct 26, 2017, 7:55 PM
Scott Q Harper, PhD reviews work at his lab at Nationwide Children's Hospital.
#
May 18, 2017, 6:01 PM
Genea Biocells scientists presented work from four disease modeling projects.
#
May 1, 2017, 3:40 PM
Interview of Dr. Joel Chamberlain regarding her lab's work on therapy development.
#
Oct 25, 2016, 9:51 AM
Development of an in vitro model of FSHD innate immunity.
#
Jul 14, 2016, 6:20 PM
Implications for FSHD and therapeutic developments
#
Jun 27, 2015, 5:05 PM
A new study suggests it may be possible to re-silence the DUX4-containing DNA array.
#
Mar 17, 2015, 2:58 PM
FSHD was a hot topic at the MDA scientific conference in Washington D.C.
#
Jun 3, 2014, 9:22 PM
Amanda Rickard, a member of the Miller Lab at the University of Washington, submitted this article reviewing the ASGCT Conference held May 21-24, 2014.
#
Jan 18, 2014, 7:36 PM
Dr. Kathryn Wagner provides a much needed tool.
#
Mar 28, 2013, 4:26 PM
A French language presentation of excerpts from the exposition "FSH, the other myopathy" in March and April.
#
Mar 6, 2013, 4:21 PM
An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells.
#
Feb 6, 2013, 3:34 PM
Using model organisms to identify new therapies and to understand the pathogenesis of FSHD.
#
Feb 6, 2013, 9:56 AM
Final progress update from FSH Scholar Barbara Page.